KU Leuven vaccine candidate protects against Covid-19 and yellow fever

December 01, 2020

Virologists at the Rega Institute at KU Leuven (Belgium) have developed a vaccine candidate against Covid-19 based on the yellow fever vaccine, which as a result also works against yellow fever. Results published today in Nature show that the vaccine protects hamsters from infection with the SARS-CoV-2 coronavirus after a single dose. The vaccine is also effective in monkeys. The team is currently preparing for clinical trials.

To engineer their vaccine, tentatively named RegaVax, the team led by Professor Johan Neyts and Kai Dallmeier inserted the genetic code of the SARS-CoV-2 spikes into the genetic code of the yellow fever vaccine. The researchers tested the vaccine in healthy hamsters and monkeys. Another group of the animals received a placebo.

The researchers first vaccinated the hamsters and then dripped the virus into their noses. Ten days after a single vaccine dose, most of the hamsters were protected against the virus. Three weeks after vaccination, all hamsters were protected. "They also didn't develop any lung infections. The lungs of the hamsters in the control groups, by contrast, showed clear signs of infection and disease," Neyts explains.

The team also tested the vaccine in monkeys. "In some of the monkeys, we observed neutralising antibodies already seven days after vaccination. After fourteen days, high titers of neutralizing antibodies were measured in all animals. This is very fast. Moreover, in the vaccinated animals, the virus was completely or nearly completely gone from their throats."

Long-lasting immunity

"Ours is the only vaccine currently in development against Covid-19 that also protects against yellow fever," explains professor Neyts. Previously, the Rega team used the yellow fever vaccine as the foundation for vaccine candidates against Zika, Ebola, and rabies. "The effectiveness and safety of the yellow fever vaccine, which has been in use for 80 years, is well-established. More than 500 million people have already received this vaccine. One dose offers fast protection against yellow fever that in nearly all cases lasts for life."

"A vaccine that works against Covid-19 and yellow fever could offer an important contribution to the WHO's campaign to eradicate yellow fever by 2026," Neyts continues. "Especially now that we know there are mosquito species present in Asia that can transmit the yellow fever virus."

RegaVax works after one dose, unlike many of the front-runners in the race today, which require a repeat vaccination after one month. "This has important logistical implications, in particular for countries with a less advanced medical system," explains professor Neyts. "Additionally, we expect that the vaccine will offer long-lasting immunity to Covid-19. It could therefore be an ideal candidate for repeat vaccinations when immunity decreases in people who have received one of the first-generation vaccines."

Finally, the vaccine can be stored at 2-8 °C, while some vaccines require a cold chain with temperatures down to -70 °C. That's already challenging in the Western world, but it may be nearly impossible to vaccinate large populations in remote tropical and subtropical regions," Neyts explains.

"An inexpensive, single-dose vaccine that rapidly protects against infection, that can be stored and transported at fridge temperature, and that may, like the yellow fever vaccine on which it is based, result in long-lasting immunity, provides an important and much-needed diversification of the Covid-19 vaccine landscape," Neyts concludes.

His team is now preparing for clinical trials next year and has joined forces with a specialised and accredited company that will produce the vaccine candidate for testing in humans.

New technique

RegaVax is a vector vaccine: it uses the genetic code of the yellow fever vaccine virus as a carrier (or vector) for the genetic code of the coronavirus spikes. "When working with a related virus, such as the Zika virus, pieces of the genetic code of the yellow fever vaccine virus are swapped with a similar piece of the code of the targeted virus. Using this strategy the team recently developed a Zika vaccine candidate. However, since SARS-CoV-2 is unrelated to yellow fever, a new technology had to be developed to insert an entirely unrelated genetic sequence in the yellow fever vaccine backbone. This concerns an important innovation in the vaccine field."

Virus inhibitors

"Mind you: vaccines are not a solution for people who are already ill. That is why we are also developing a cure to help Covid-19 patients," Neyts concludes. "We recently published on the protective activity of the Japanese flu drug favipiravir in hamsters. We have identified some other existing medicines or combinations thereof that inhibit the virus. We are now first exploring their effect in infected hamsters. At the same time, we aim to develop new and powerful virus inhibitors against SARS-CoV-2. For this purpose, we have already tested more than 1.6 million molecules in our fully automated high biosafety laboratory. We're looking for a needle in a haystack."

KU Leuven

Related Vaccination Articles from Brightsurf:

US adults' likelihood of accepting COVID-19 vaccination
In this survey study of U.S. adults, vaccine-related attributes and political characteristics were associated with self-reported preferences for choosing a hypothetical COVID-19 vaccine and self- reported willingness to receive vaccination.

Vaccination insights
While scientists race to develop and test a vaccine effective against SARS-CoV-2, the virus that causes COVID-19, recent studies have indicated that countries with widespread BCG vaccination appear to be weathering the pandemic better than their counterparts.

Wording of vaccination messages influences behavior
An experiment by Washington State University researchers revealed that relatively small differences in messages influenced people's attitudes about the human papillomavirus or HPV vaccine, which has been shown to help prevent cancer.

Addressing HPV vaccination concerns
Research from the Harvard Pilgrim Health Care Institute finds a promising avenue for addressing vaccine hesitancy around HPV vaccine.

Virtual reality could help flu vaccination rates
Using a virtual reality simulation to show how flu spreads and its impact on others could be a way to encourage more people to get a flu vaccination, according to a study by researchers at the University of Georgia and the Oak Ridge Associated Universities in Oak Ridge, Tennessee.

Religion associated with HPV vaccination rate for college women
A survey of female college students finds 25% had not been vaccinated for HPV and religion may be a contributing factor.

Measles vaccination: 'All for one and one for all'
A commentary by researchers addresses the specter of clinical, ethical, public health and legal concerns that have been raised because of the recent measles outbreaks in New York.

New single vaccination approach to killer diseases
Scientists from the University of Adelaide's Research Centre for Infectious Diseases have developed a single vaccination approach to simultaneously combat influenza and pneumococcal infections, the world's most deadly respiratory diseases.

Vaccination may help protect bats from deadly disease
A new study shows that vaccination may reduce the impact of white-nose syndrome in bats, marking a milestone in the international fight against one of the most destructive wildlife diseases in modern times.

Parents reassured febrile seizures following vaccination not dangerous
New University of Sydney research finds that febrile seizures after vaccination are rare, not serious and are no different to febrile seizures due to other causes such as from a virus.

Read More: Vaccination News and Vaccination Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.